The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study
Latest Information Update: 05 Oct 2022
At a glance
- Drugs Surufatinib (Primary) ; Toripalimab (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 07 Jun 2022 Status changed from not yet recruiting to recruiting, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results (n=10) assessing efficacy and safety of surufatinib plus toripalimab in locally advanced thyroid cancer in the neoadjuvant setting, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 26 Aug 2020 New trial record